Metabolic: GLP-1/GIP vs oral GH secretagogue

MK-677 vs Tirzepatide

Comparing MK-677 and Tirzepatide across evidence, dosing, mechanisms, and research areas.

Compound A

vs

Compound B

Category

hormone

weightloss

Molecular weight

—

4813.45 g/mol

Half-life

—

~5 days (120 hours)

Admin routes

—

subcutaneous

Research areas

—

Weight loss / obesityType 2 diabetesMetabolic syndromeObstructive sleep apneaHeart failure with preserved ejection fraction (HFpEF)NASH / MASH

Typical dosing

—

2500–15000 mcg · 1x weekly · Ongoing (titrate over 20+ weeks)

FDA status

research-only

FDA-approved (Mounjaro for T2D Nov 2022, Zepbound for weight management Nov 2023)

WADA status

—

Not prohibited (as of 2026)

PubMed studies

—

1,871

Full profile →Full profile →

More Comparisons

bpc-157 vs tb-500 cjc-1295 vs ipamorelin semaglutide vs tirzepatide ghk-cu vs ghk ghrp-2 vs ghrp-6 igf-1-lr3 vs igf-1-des semax vs selank epithalon vs ghk-cu bpc-157 vs ghk-cu pt-141 vs kisspeptin semaglutide vs aod-9604 bpc-157 vs cerebrolysin tesamorelin vs cjc-1295 mk-677 vs ipamorelin thymosin-alpha-1 vs ll-37 mots-c vs nad-plus cerebrolysin vs semax epithalon vs nad-plus semaglutide vs retatrutide